NeuroVive Pharmaceutial AB (STO:NVP), a leading mitochondrial medicine company, is able to present further details regarding the previously communicated exclusive, worldwide licensing agreement with OnCore Biopharma, Inc. (OnCore) for the oral treatment of hepatitis B virus (HBV). This information will be made public with NeuroVive´s consent as a part of OnCore´s current process towards a merger with Tekmira Pharmaceutical.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
